Medicament for preventing and controlling alzheimer's disease

A technology for Alzheimer's disease and drugs, applied in the field of biomedicine, can solve the problems of bleeding, inflammatory response microvessels, etc., achieve broad clinical application prospects, avoid repeated drug administration, and reduce treatment costs

Inactive Publication Date: 2008-04-02
王延江 +2
View PDF0 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, immunotherapy has some serious side effects, includ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for preventing and controlling alzheimer's disease
  • Medicament for preventing and controlling alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0060] The preparation method of the present invention is as follows: firstly, the scFv gene is cloned from the pGEX-6P-scFv plasmid by using the polymerase chain reaction (PCR) method, and the secretory signal peptide and the enzyme cutting site are introduced, and then enzyme cutting is connected into the AAV plasmid pSNAV1 , constituting the pSNAV1-scFv plasmid. The signal peptide sequence is: atggactgga cctggaggat cctcttcttg gtggcagcag ccacaggagc ccactcc. The resulting plasmid was transformed and amplified. Plasmids were extracted and identified by one-way DNA sequencing. The pSNAV1-scFv plasmid was introduced into BHK-21 cells, and G418 selected pSNAV1-scFv plasmid carrier cells. The helper virus rHSV1 / repcap containing AAV rep and cap genes is added to infect the pSNAV1-scFv vector cells for virus replication and packaging. Collect the culture supernatant and centrifuge. Add polyethylene glycol and NaCl, incubate, centrifuge, and collect the rAAV virus particle preci...

experiment example

[0064] 1. Inhibitory effect of scFv on Aβ42 monomer polymerization

[0065] To test the effect of scFv on Aβ aggregation, 30 μg Aβ42 and equimolar scFv were mixed to a final concentration of 25 μM. Incubate at 37°C for 7 days. The results showed that after Aβ42 and scFv-GST were mixed and incubated at equimolar concentrations, the fluorescence intensity of Thioflavine T was significantly lower than that of the Aβ42 alone incubation group and the Aβ42 and GST protein co-incubation group, as shown in Figure 1, in Figure 1: Aβ refers to the group incubated with Aβ42 monomer alone, Aβ+scFv refers to the group incubated with Aβ42 monomer and scFv-GST protein, Aβ+GST refers to the group incubated with Aβ42 monomer and GST protein, and GST refers to the group incubated with GST protein alone . It can be seen from Figure 1 that there is no significant difference in the fluorescence intensity of the positive control Aβ42 incubation group alone and the Aβ42 and GST protein co-incubati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A medicine for curing alzheimer disease is characterized in that a recombinant virus of gene transfection is regarded as a carrier; the front end of one, two or a plurality of anti A beta single-chain antibody genes is respectively connected with a secretion signal peptide dna sequence; and then the anti A beta single-chain antibody genes are inserted into the recombinant virus gene; finally a packaged product is formed through the recombinant virus. The invention can produce anti A beta single-chain antibody in the body by transfecting the anti A beta single-chain antibody genes capable of prohibiting A beta monomer isomerization and promoting A beta polymer depolymerization on the periphery and in the brains, so as to express scFv in the body for a long time, to effectively remove the A beta in the brains with alzheimer disease, prevent inflammatory reaction of the central nervous system and side effect of capillary bleeding produced in the anti A beta immune therapy, avoid repeated feeding of the anti A beta medicine, and reduce the curing cost. The invention provides a safe and effective novel technology of curing alzheimer disease which works for long and has broad clinical application prospect.

Description

(1) Technical field [0001] The invention relates to the field of biomedicine, in particular to a medicine for preventing and treating Alzheimer's disease. (two), background technology [0002] The English word for Alzheimer's disease is Alzheimer's disease, usually abbreviated as AD. AD is a progressive neurodegenerative disease characterized by dementia, and is currently an important disease that endangers the health and life of the elderly. At present, there are about 24.3 million AD patients in the world, and 4.6 million new cases are diagnosed every year. It is estimated that by 2040, there will be a total of 81 million AD patients worldwide. AD has become the 7th-8th cause of death among the current population, and the 4th-5th cause of death among people over 65 years old. The economic burden brought by AD to the family and society ranks third among all diseases, second only to heart disease and cancer. my country is facing a severe situation of population aging and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61P25/28C12N15/11C12N15/861
CPCC12N2710/10332A61K35/13A61K35/761C12N15/86C07K2317/622C12N2710/10343C07K16/18A61K35/76A61P25/28A61K2300/00
Inventor 王延江周新富周华东
Owner 王延江
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap